InMed Pharmaceuticals EBIT

InMed Pharmaceuticals (INM) currently reports a EBIT of $-9.6B as of March 2026. That compares with $-14B in the prior-year period — up 29.4% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore InMed Pharmaceuticals's EBIT history and peer comparisons.

InMed Pharmaceuticals's EBIT increased from $-14B to $-9.6B — a 29.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

InMed Pharmaceuticals's EBIT of $-9.6B is lower than the Healthcare sector average of $22B. That is roughly 142.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

InMed Pharmaceuticals reported $-9.6B in EBIT as of March 2026. That compares with $-14B in the prior-year period — up 29.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-9.6B, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for InMed Pharmaceuticals, and consider following INM for alerts when major investors trade the stock.